Monica Gireud

Monica Gireud

Auto-generated profile, based on publicly available information

Monica Gireud

University of Texas Health Science Center at San Antonio

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2020 in The Neuroscientist
Verified
Journal Article
Closed access
PDF file
MGMonica Gireud-Goss
Monica Gireud-Goss
AMAlexis F. Mack
Alexis F. Mack
LMLouise D. McCullough
Louise D. McCullough
AUAkihiko Urayama
Akihiko Urayama
Cerebral hemorrhage, a devastating subtype of stroke, is often caused by hypertension and cerebral amyloid angiopathy (CAA). Pathological evidence of CAA is detected in approximately half of all individuals over the age of 70 and is associated with cortical microinfarcts and cognitive impairment. The underlying pathophysiology of CAA is characterized by accumulation of pathogenic amyloid β (Aβ) fragments of amyloid precursor protein in the cerebral vasculature. Vascular deposition of Aβ damages the vessel wall, results in blood-brain barrier (BBB) leakiness, vessel occlusion or rupture, and leads to hemorrhages and decreased cerebral blood flow that negatively affects vessel integrity and cognitive function. Currently, the main hypothesis surrounding the mechanism of CAA pathogenesis is that there is an impaired clearance of Aβ peptides, which includes compromised perivascular drainage as well as dysfunction of BBB transport. Also, the immune response in CAA pathogenesis plays an important role. Therefore, the mechanism by which Aβ vascular deposition occurs is crucial for our understanding of CAA pathogenesis and for the development of potential therapeutic options.

18 September 2012 in Cancer
Verified
Journal Article
Open access
PDF file
PZPeter E. Zage
Peter E. Zage
NSNatalie Sirisaengtaksin
Natalie Sirisaengtaksin
YLYin Liu
Yin Liu
MGMonica Gireud
Monica Gireud
BBBrandon S. Brown Bs
Brandon S. Brown Bs
ABAndrew J. Bean
Andrew J. Bean
BACKGROUND: The UBE4B gene, which is located on chromosome 1p36, encodes a ubiquitin ligase that interacts with hepatocyte growth factor‐regulated tyrosine kinase substrate (Hrs), a protein involved in epidermal growth factor receptor (EGFR) trafficking, suggesting a link between EGFR trafficking and neuroblastoma pathogenesis. The authors analyzed the roles of UBE4B in the outcomes of patients with neuroblastoma and in neuroblastoma tumor cell proliferation, EGFR trafficking, and response to EGFR inhibition.METHODS: The association between UBE4B expression and the survival of patients with neuroblastoma was examined using available microarray data sets. UBE4B and EGFR protein levels were measured in patient tumor samples, EGFR degradation rates were measured in neuroblastoma cell lines, and the effects of UBE4B on neuroblastoma tumor cell growth were analyzed. The effects of the EGFR inhibitor cetuximab were examined in neuroblastoma cells that expressed wild‐type and mutant UBE4B.RESULTS: Low UBE4B gene expression is associated with poor outcomes in patients with neuroblastoma. UBE4B overexpression reduced neuroblastoma tumor cell proliferation, and UBE4B expression was inversely related to EGFR expression in tumor samples. EGFR degradation rates correlated with cellular UBE4B levels. Enhanced expression of catalytically active UBE4B resulted in reduced sensitivity to EGFR inhibition.CONCLUSIONS: The current study demonstrates associations between UBE4B expression and the outcomes of patients with neuroblastoma and between UBE4B and EGFR expression in neuroblastoma tumor samples. Moreover, levels of UBE4B influence neuroblastoma tumor cell proliferation, EGFR degradation, and response to EGFR inhibition. These results suggest UBE4B‐mediated growth factor receptor trafficking may contribute to the poor prognosis of patients who have neuroblastoma tumors with 1p36 deletions and that UBE4B expression may be a marker that can predict responses of neuroblastoma tumors to treatment. Cancer 2013. © 2012 American Cancer Society.

1 January 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NSNatalie Sirisaengtaksin
Natalie Sirisaengtaksin
MGMonica Gireud
Monica Gireud
QYQing Yan
Qing Yan
YKYoshihisa Kubota
Yoshihisa Kubota
DMDenisse Meza
Denisse Meza
ABAndrew J. Bean
Andrew J. Bean
The signaling of plasma membrane proteins is tuned by internalization and sorting in the endocytic pathway prior to recycling or degradation in lysosomes. Ubiquitin modification allows recognition and association of cargo with endosomally associated protein complexes, enabling sorting of proteins to be degraded from those to be recycled. The mechanism that provides coordination between the cellular machineries that mediate ubiquitination and endosomal sorting is unknown. We report that the ubiquitin ligase UBE4B is recruited to endosomes in response to epidermal growth factor receptor (EGFR) activation by binding to Hrs, a key component of endosomal sorting complex required for transport (ESCRT) 0. We identify the EGFR as a substrate for UBE4B, establish UBE4B as a regulator of EGFR degradation, and describe a mechanism by which UBE4B regulates endosomal sorting, affecting cellular levels of the EGFR and its downstream signaling. We propose a model in which the coordinated action of UBE4B, ESCRT-0, and the deubiquitinating enzyme USP8 enable the endosomal sorting and lysosomal degradation of the EGFR.

26 April 2011 in Cancer
Verified
Journal Article
Open access
PDF file
ASAkanksha Singh
Akanksha Singh
CRChristopher Rokes
Christopher Rokes
MGMonica Gireud
Monica Gireud
SFStephen Fletcher
Stephen Fletcher
JBJames Baumgartner
James Baumgartner
VGVidya Gopalakrishnan
Vidya Gopalakrishnan
BACKGROUND: The repressor element‐1 silencing transcription factor (REST) is a repressor of neuronal genes. Its expression is associated with poor neuronal differentiation in many neuroblastoma patient samples and cell lines. Because retinoic acid promotes neuronal differentiation, the authors postulated that it involves modulation of REST expression.METHODS: The expression of REST and of an S‐phase kinase‐associated protein 1/cullin 1/F‐box (SCF) protein complex that contains the F‐box protein β‐transducin repeat‐containing protein (β‐TRCP) (SCFβ‐TRCP) in neuroblastoma tumor samples and cell lines was analyzed by immunofluorescence and Western blot analysis. SK‐N‐SH and SK‐N‐AS cells were treated with retinoic acid and MG‐132 to measure proteasomal degradation of REST by Western blot and quantitative real‐time polymerase chain reaction analyses. Immunoprecipitation and coimmunoprecipitation assays were done in SK‐N‐AS cells that were transfected either with a control plasmid or with an enhanced green fluorescent protein‐SCFβ‐TRCP–expressing plasmid.RESULTS: Several neuroblastoma patient samples and cell lines displayed elevated REST expression. Although, REST transcription increased upon retinoic acid treatment in SK‐N‐SH and SK‐N‐AS cells, REST protein levels declined, concomitant with the induction of neuronal differentiation, in SK‐N‐SH cells but not in SK‐N‐AS cells. MG‐132 treatment countered the retinoic acid‐mediated decline in REST protein. SCFβ‐TRCP, a known REST‐specific E3‐ligase, was poorly expressed in many neuroblastoma samples, and its expression increased upon retinoic acid treatment in SK‐N‐SH cells but declined in SK‐N‐AS cells. Ectopic expression of SCFβ‐TRCP in SK‐N‐AS cells promoted REST ubiquitination and degradation and neuronal differentiation.CONCLUSIONS: The current results indicated that elevated transcription of REST compounded by its impaired degradation by SCFβ‐TRCP may contribute to the failure of these tumors to differentiate in response to retinoic acid. Cancer 2011;. © 2011 American Cancer Society.

22 August 2020 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
MGMonica Gireud-Goss
Monica Gireud-Goss
SRSahily Reyes
Sahily Reyes
RTRitika Tewari
Ritika Tewari
APAnthony Patrizz
Anthony Patrizz
MHMatthew D. Howe
Matthew D. Howe
ABAndrew J. Bean
Andrew J. Bean

1 March 2016 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
SWSarah B. Whittle
Sarah B. Whittle
SRSahily Reyes
Sahily Reyes
MDMelissa Du
Melissa Du
MGMonica Gireud
Monica Gireud
LZLinna Zhang
Linna Zhang
PZPeter E. Zage
Peter E. Zage
Background: Outcomes for children with high-risk neuroblastoma are poor, and improved understanding of the mechanisms underlying neuroblastoma pathogenesis, recurrence, and treatment resistance will lead to improved outcomes. Aberrant growth factor receptor expression and receptor tyrosine kinase signaling are associated with the pathogenesis of many malignancies. A germline polymorphism in the FGFR4 gene is associated with increased receptor expression and activity and with decreased survival, treatment resistance, and aggressive disease for many malignancies. We therefore investigated the role of this FGFR4 polymorphism in neuroblastoma pathogenesis. Materials and Methods: Germline DNA from neuroblastoma patients and matched controls was assessed for the FGFR4 Gly/Arg388 polymorphism by RT-PCR. Allele frequencies were assessed for association with neuroblastoma patient outcomes and prognostic features. Degradation rates of the FGFR4 Arg388 and Gly388 receptors and rates of receptor internalization into the late endosomal compartment were measured. Results: Frequency of the FGFR4 AA genotype and the prevalence of the A allele were significantly higher in patients with neuroblastoma than in matched controls. The Arg388 receptor demonstrated slower degradation than the Gly388 receptor in neuroblastoma cells and reduced internalization into multivesicular bodies. Conclusions: The FGFR4 Arg388 polymorphism is associated with an increased prevalence of neuroblastoma in children, and this association may be linked to differences in FGFR4 degradation rates. Our study provides the first evidence of a role for FGFR4 in neuroblastoma, suggesting that FGFR4 genotype and the pathways regulating FGFR4 trafficking and degradation may be relevant for neuroblastoma pathogenesis.